The FDA needs a few more weeks to decide the fate of Moderna's RSV vaccine, the company announced. A decision is now slated ...

Just days before its initial deadline, U.S. regulators say they need more time to decide whether or not to approve Moderna's ...

The regulator cited “administrative constraints,” rather than any issue with Moderna’s trial data, for missing a May 12 deadline, the company said.

Moderna on Friday said the Food and Drug Administration has postponed an approval decision on its experimental vaccine for ... t expect major delays from here onwards and FDA should be able ...

Moderna shares fell in intraday trading Friday as it said the FDA has pushed back its RSV vaccine approval decision until the ...

US regulators’ decision on whether to approve Moderna Inc.’s vaccine for RSV has been delayed due to ... get its second product to market. The FDA hasn’t informed Moderna of any issues ...

its investigational respiratory syncytial virus or RSV vaccine, will be delayed. In pre-market activity on the Nasdaq, Moderna shares were losing around 2.3 percent to trade at $119.91. The FDA ...

Moderna announced that the FDA had delayed approval of its RSV vaccine to the end of May due to "administrative constraints" ...

Moderna (NASDAQ:MRNA) shares are down just over 1% in early Friday trading after the company said the FDA ... RSV vaccine due to "administrative constraints." However, they remain on track for a ...

(Reuters) -The U.S. drug regulator has pushed back its decision ... vaccine, its only marketed product, after the pandemic. The company is seeking the FDA's approval of the shot to prevent RSV ...